Demographic data and HIV drug resistance among 108 HIV-1-infected treatment naïve VCT clients
| Parameters | Patient numbers (%) |
|---|---|
| Sex | |
| Male | 108 (100%) |
| Age | |
| 20–29 | 54 (50%) |
| 30–39 | 44 (40.7%) |
| 40–49 | 8 (7.4%) |
| >50 | 2 (1.9%) |
| Risk factor | |
| Heterosexual | 13 (12%) |
| MSM | 95 (88%) |
| V3 co-receptor | |
| CXCR4 | 28 (25.9%) |
| CCR5 | 80 (74.1%) |
| HIV subtype (n=102) | |
| B | 101 (99%) |
| C | 1 (1%) |
| Hepatitis A antibody (n=97) | |
| Positive | 9 (9.3%) |
| HBs Ag (n=107) | |
| Positive | 14 (13.1%) |
| Antihepatitis B surface antibody (n=99) | |
| Positive | 54 (54.5%) |
| Antihepatitis B core antibody (n=99) | |
| Positive | 39 (39.4%) |
| Hepatitis C antibody (n=106) | |
| Positive | 5 (4.7%) |
| GOT (range 0–35 U/L) | |
| Median (IQR) | 22 (19–27) |
| GPT (range 0–40 U/L) | |
| Median (IQR) | 25 (16–35) |
| Cortisol (µg/dL) (normal range 3.1–22.4 µg/dL) | |
| Median (IQR) | 13.3 (9.8–15.7) |
| FreeT4 (ng/dL) (normal range 0.8–1.9 µg/dL) | |
| Median (IQR) | 1.23 (1.08–1.31) |
| Syphilis serology | |
| Positive | 48 (44.4%) |
| IHA-Amoebiasis ≥32 (n=100) | |
| Positive | 8 (8.0%) |
| CMV-IgG (n=66) | |
| Positive | 64 (97.0%) |
| Toxoplasma-IgG (n=99) | |
| Positive | 4 (4.5%) |
| HIV viral load (log) (IU/mL) | |
| Median (IQR) | 4.6 (4.0–5.0) |
| CD4 count (cells/µL) | |
| Median (IQR) | 342 (209–454) |
| HIV drug-resistance associated mutation | |
| Resistance | 10 (9.3%) |
CMV, cytomegalovirus; GOT, glutamic oxaloacetic transaminase; GPT, glutamic pyruvic transaminase; HBs Ag, hepatitis B surface antigen; IHA, indirect haemagglutination; MSM, men who have sex with men.